James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

S&P 500 Index: Why Wall Street Should Fear Week 38

The S&P 500 Index isn't ruled by history. Still, don't be foolish and blow off the calendar-based tendency for stocks when it's this reliable.

Why GoPro Inc (GPRO), Sprint Corp (S) and Deutsche Bank AG (USA) (DB) Are 3 of Today’s Worst Stocks

Sprint (S), GoPro (GPRO) and Deutsche Bank (DB) were just not going to happen on Tuesday, regardless of what the market did.

Allergan plc Ordinary Shares: What Is AGN Getting for Its Billion Dollars?

Allergen (AGN) is in a buying mood, and can afford to buy Tobira (TBRA). But, that doesn't mean there's a big payback for the investment.

Why Twitter Inc (TWTR), Deutsche Bank AG (USA) (DB) and WebMD Health Corp. (WBMD) Are 3 of Today’s Worst Stocks

Deutsche Bank (DB), WebMD Health (WBMD) and Twitter (TWTR) were doomed from the start of today's trading action.

Valeant Pharmaceuticals Intl Inc (VRX) Just Doesn’t Get it

Valeant Pharmaceuticals (VRX) CEO Joe Papa may be an experienced pharmaceutical industry veteran, but he still has at least one lesson to learn the hard way.